Floatz logo

Pri-724

Chronic Myeloid Leukemia

Prism Pharma Co., Ltd.Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

86 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
METHOTREXATE
M.D. Anderson Cancer Center
Phase 3BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB

View all 50 →

Same molecule, other indications

Pri-724 is also rated in:

cirrhosis of liverDormant
BB
Indicative ·
69 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →
hepatitis C virus infectionDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →